Age, spinal cord injury severity, C-reactive protein levels, urination modes, and pain severity all significantly impact incidence.

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

A new model may help identify neurogenic bladder and other complications in patients with spinal cord injuries.